Jack Henningfield, PhD
Expertise In his far-reaching career, Jack’s research and contributions to drug regulation and public policy have contributed to the development of important medicines and other approaches for addressing addiction and…
Expertise In his far-reaching career, Jack’s research and contributions to drug regulation and public policy have contributed to the development of important medicines and other approaches for addressing addiction and…
June 11-15, 2022 | MINNEAPOLIS, MN Jack Henningfield, August Buchhalter, and Ryan Lanier will be attending CPDD. VIEW CONFERENCE WEBSITE…
December 3-6, 2023 | Tampa, FL Jack Henningfield will be attending. VIEW CONFERENCE Posters:No Indication of Abuse or Withdrawal Potential with Esmethadone (REL-1017): Results From Two Phase 3 Randomized Placebo-Controlled…
September 10-12, 2023 | Bellevue, WA Jack Henningfield will be attending and participating in a panel discussion. VIEW CONFERENCE Discussion: Symposium 6: The Tightrope of Substance Abuse Potential: The Preclinical…
September 27-28, 2023 | Rockville, MD Jack Henningfield, Judy Ashworth, and Ryan Lanier will be attending. VIEW CONFERENCE…
June 17-21, 2023 | Denver, CO Judy Ashworth, Jack Henningfield, August Buchhalter, Ryan Lanier and Caitlyn Durgin will be attending. VIEW CONFERENCE WEBSITE Posters: Within-Subject Variations in Opioid Sensitivity Across…
Jack Henningfield, PhD, Vice President, Research, Health Policy, and Abuse Liability, Pinney Associates Presented as part of the NIH Psilocybin Speaker Series, April 22-June 10, 2021 VISIT THE SPEAKER…
Henningfield JE, Babin J, Boyer EW, Brown P, Garcia-Romeu A, Griffiths RR, Grundmann O, Hemby SE, McCurdy CR, Raffa RB, Swogger MT, Walsh Z November 28, 2018 View PDF…